n.a. (SNTS)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Shares Outstanding 67.14M
Div & Yield N.A. (N.A)

Choppy, Treacherous Action

Volume is thin, and despite the lack of news, the selling pressure is on.

Santarus To Present At Seventh Annual JMP Securities Healthcare Conference

Santarus To Present At Seventh Annual JMP Securities Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus Reaches New 52-Week High (SNTS)

Santarus Reaches New 52-Week High (SNTS)

Santarus (Nasdaq:SNTS) hit a new 52-week high Tuesday as it is currently trading at $6.97, above its previous 52-week high of $6.93 with 426,605 shares traded as of 3:50 p.m. ET. Average volume has been 520,800 shares over the past 30 days.

Santarus Stock Falls On Unusually High Volume (SNTS)

Santarus Stock Falls On Unusually High Volume (SNTS)

Santarus (Nasdaq:SNTS) is trading at unusually high volume Wednesday with two million shares changing hands. It is currently at 4.6 times its average daily volume and trading down 36 cents (-5.3%).

Santarus Stock Hits New 52-Week High (SNTS)

Santarus Stock Hits New 52-Week High (SNTS)

Santarus (Nasdaq:SNTS) hit a new 52-week high Tuesday as it is currently trading at $6.63, above its previous 52-week high of $6.60 with 616,161 shares traded as of 11:15 a.m. ET. Average volume has been 428,400 shares over the past 30 days.

Santarus To Present At Jefferies 2012 Global Healthcare Conference

Santarus To Present At Jefferies 2012 Global Healthcare Conference

Santarus, Inc. (NASDAQ:SNTS) today announced that Gerald T.

Santarus Announces Presentation Of UCERIS Phase III Extended Use Data At Digestive Disease Week Meeting

Santarus Announces Presentation Of UCERIS Phase III Extended Use Data At Digestive Disease Week Meeting

Santarus, Inc. (NASDAQ: SNTS) today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS ™ ...

Santarus Inc. Stock Downgraded (SNTS)

Santarus Inc. Stock Downgraded (SNTS)

Santarus (Nasdaq:SNTS) has been downgraded by TheStreet Ratings from from a buy to hold.

Santarus' CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Santarus' CEO Presents At Bank Of America Merrill Lynch 2012 Health Care Conference (Transcript)

Santarus' CEO Presents at Bank of America Merrill Lynch 2012 Health Care Conference (Transcript)

Santarus Stock Hits New 52-Week High (SNTS)

Santarus Stock Hits New 52-Week High (SNTS)

Santarus (Nasdaq:SNTS) hit a new 52-week high Friday as it is currently trading at $6.54, above its previous 52-week high of $6.50 with 329,808 shares traded as of 12:35 p.m. ET. Average volume has been 397,500 shares over the past 30 days.

Santarus' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Santarus' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Santarus' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Santarus Reports First Quarter 2012 Financial Results

Santarus Reports First Quarter 2012 Financial Results

Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2012.

29 Drugs Facing FDA Approval in 2012

29 Drugs Facing FDA Approval in 2012

An updated calendar listing FDA drug approval decisions and advisory panels for the remainder of 2012.

Santarus Stock Hits New 52-Week High (SNTS)

Santarus Stock Hits New 52-Week High (SNTS)

Santarus (Nasdaq:SNTS) hit a new 52-week high Friday as it is currently trading at $6.28, above its previous 52-week high of $6.25 with 94,584 shares traded as of 1:13 p.m. ET. Average volume has been 414,100 shares over the past 30 days.

Santarus Appoints Alessandro E. Della Chà And Matthew W. Strobeck To Board Of Directors

Santarus Appoints Alessandro E. Della Chà And Matthew W. Strobeck To Board Of Directors

Santarus, Inc. (NASDAQ: SNTS) today announced the appointment of Alessandro E.

Santarus To Present At 11th Annual Needham Healthcare Conference

Santarus To Present At 11th Annual Needham Healthcare Conference

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Follow the Hot Money

It's easier to find the hot action in a slow market because it's more concentrated.

Staying Prepared

I'm refining my buy list and prioritizing the names I'm pursuing as charts develop.

Santarus' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Santarus' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Santarus' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Santarus Reports Fourth Quarter And Full Year 2011 Financial Results

Santarus Reports Fourth Quarter And Full Year 2011 Financial Results

Santarus, Inc. (NASDAQ: SNTS) today reported financial and operating results for the three and 12 month periods ended December 31, 2011.

Santarus Stock Gaps Up On Today's Open (SNTS)

Santarus Stock Gaps Up On Today's Open (SNTS)

Shares of Santarus (Nasdaq:SNTS) were gapping up Monday morning with an open price 11.3% higher than Friday's closing price. The stock closed at $4.50 yesterday and opened today's trading at $5.01.

Santarus To Present At March Investment Conferences

Santarus To Present At March Investment Conferences

Santarus, Inc. (NASDAQ: SNTS) today announced that Gerald T.

Santarus To Hold Fourth Quarter And Full Year 2011 Financial Results Conference Call On March 5

Santarus To Hold Fourth Quarter And Full Year 2011 Financial Results Conference Call On March 5

Santarus, Inc. (NASDAQ: SNTS) today announced that it will release fourth quarter and full year 2011 financial results after market close on Monday, March 5, 2012.

Santarus And Depomed Announce Settlement With Lupin Of GLUMETZA Patent Litigation

Santarus And Depomed Announce Settlement With Lupin Of GLUMETZA Patent Litigation

Santarus, Inc. (NASDAQ:SNTS) and Depomed, Inc.

Santarus Announces FDA Acceptance Of UCERIS New Drug Application For Induction Of Remission Of Active Ulcerative Colitis

Santarus Announces FDA Acceptance Of UCERIS New Drug Application For Induction Of Remission Of Active Ulcerative Colitis

Santarus, Inc. (NASDAQ: SNTS) today announced that the U.

Santarus Increases Revolving Line Of Credit To $35 Million And Extends Maturity To February 2015

Santarus Increases Revolving Line Of Credit To $35 Million And Extends Maturity To February 2015

Santarus, Inc. (NASDAQ: SNTS) today announced that it has increased its revolving line of credit with Comerica Bank from $25 million to $35 million and extended the maturity from July 11, 2013 to February 13, 2015.

Santarus Announces Initiation Of Phase IIIb Study With UCERIS In Patients With Mild Or Moderate Active Ulcerative Colitis

Santarus Announces Initiation Of Phase IIIb Study With UCERIS In Patients With Mild Or Moderate Active Ulcerative Colitis

Santarus, Inc. (NASDAQ: SNTS) today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug...

Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE

Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE

Santarus, Inc. (NASDAQ: SNTS) today announced that it has commenced promotion of prescription FENOGLIDE ® (fenofibrate) tablets 40 mg and 120 mg to selected physicians in the U.

5 Stocks Hitting New 52-Week Highs

5 Stocks Hitting New 52-Week Highs

When a stock is hitting new 52-week highs, it often means that the uptrend is very strong and the buyers are in full control.

Santarus' CEO Discusses Business Update Conference Call Transcript

Santarus' CEO Discusses Business Update Conference Call Transcript

Santarus' CEO Discusses Business Update Conference Call Transcript